Tumor Biology

, Volume 37, Issue 12, pp 15873–15881 | Cite as

A novel model for identification of prognostic indicator for clinical outcome of squamous cell lung carcinoma

  • Kai Duan
  • Li Li
  • Xiao-dong Tan
  • Ping Yin
Original Article


Squamous cell carcinoma of the lung (SCCL) is the most common and aggressive lung tumor with poor clinical outcome. Identification and development of potential genes in prognostic process could be beneficial for clinical management. Sequencing data of 300 SCCL samples at level 3 were downloaded from The Cancer Genome Atlas (TCGA) data portal. Single-factor survival analysis was performed by the Kaplan-Meier method. Functional annotation was conducted on the high-frequency genes filtered out by 1000 times of the least absolute shrinkage and selectionator operator regression analysis. Meanwhile, multi-factor survival analysis was conducted and ROC curve were produced. Risk coefficient and expression level of each gene were used in the division of high-risk and low-risk genes. The number of high-risk genes of each sample was obtained, and the survival condition of different samples was analyzed. Finally, the number of optimal high-risk genes was obtained. Seven thousand nine hundred ninety-eight differential expressed mRNAs were obtained, and 2041 potential prognostic genes were screened out. Twenty one of the 22 high-frequency genes were showed to have significant impact on prognostic process. Single-factor analysis was performed on the 22 models, and eight efficient models were obtained, and seven among them were proven to be significant. By random testing, ≥5 genes and ≥6 genes were proven to be most stable and ≥6 genes were finally recognized as the beneficial indicator to distinguish lung squamous cell carcinoma. Twenty-two potential genes differentially expressed in lung squamous cell carcinoma were identified as potential prognostic indicator in clinical outcome, and the novel model in this study could be applied in other cancer types.


Lung squamous cell carcinoma TCGA Survival analysis LASSO regression 


  1. 1.
    Levi F, Maisonneuve P, Filiberti R, La Vecchia C, Boyle P. Cancer incidence and mortality in Europe. Soz Präventivmed. 1989;34:S3–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor–stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005;11:8288–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Sanchez‐Palencia A, Gomez‐Morales M, Gomez‐Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer. 2011;129:355–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Vavalà T, Levra MG, Novello S. Lung cancer in never smokers: a different disease. Curr Respir Care Rep. 2014;3:26–34.CrossRefGoogle Scholar
  6. 6.
    Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Zudaire I, Lozano MD, Vazquez M, Pajares MJ, Agorreta J, Pio R, Zulueta JJ, Yankelevitz D, Henschke C, Montuenga LM. Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. 2008.Google Scholar
  8. 8.
    Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000;6:2604–10.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2000;1:1131–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30.CrossRefPubMedGoogle Scholar
  11. 11.
    McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.CrossRefGoogle Scholar
  12. 12.
    Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55:51–6.PubMedGoogle Scholar
  13. 13.
    O’Quigley J, Moreau T. Cox’s regression model: computing a goodness of fit statistic. Comput Methods Prog Biomed. 1986;22:253–6.CrossRefGoogle Scholar
  14. 14.
    Tibshirani R. The lasso method for variable selection in the cox model. Stat Med. 1997;16:385–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Goeman JJ. L1 penalized estimation in the cox proportional hazards model. Biom J. 2010;52:70–84.PubMedGoogle Scholar
  16. 16.
    Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4:44–57.CrossRefGoogle Scholar
  17. 17.
    Heagerty PJ, Lumley T, Pepe MS. Time-dependent roc curves for censored survival data and a diagnostic marker. Biometrics 2000: 337–344.Google Scholar
  18. 18.
    Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci. 2013;110:7413–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRefPubMedGoogle Scholar
  20. 20.
    Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69:5776–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res. 2012;18:2360–73.CrossRefPubMedGoogle Scholar
  22. 22.
    Near RI, Zhang Y, Makkinje A, Borre PV, Lerner A. And‐34/bcar3 differs from other NSP homologs in induction of anti‐estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. J Cell Physiol. 2007;212:655–65.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-mir-31 for prognosis. Clin Cancer Res. 2011;17:6802–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Nevins JR, Harpole D, Potti A, West M, Dressman H. Prediction of lung cancer tumor recurrence. Google Patents, 2007.Google Scholar
  25. 25.
    Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.CrossRefPubMedGoogle Scholar
  26. 26.
    Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor flt‐1 in squamous cell lung cancer. Int J Cancer. 1997;74:64–8.CrossRefPubMedGoogle Scholar
  27. 27.
    McKee ML, Kerwin SM. Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2′-hydroxyphenyl) benzoxazole analogs of uk-1. Bioorg Med Chem. 2008;16:1775–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Williams RJ. Metal ions in biological systems. Biol Rev. 1953;28:381–412.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations